Who is sponsoring NCT00847808?

NCT00847808 is sponsored by Takeda.

What condition does NCT00847808 study?

NCT00847808 studies Gastroesophageal Reflux.

What drugs are being tested in NCT00847808?

Interventions: Dexlansoprazole MR QD.

What is the status of NCT00847808?

NCT00847808 is currently COMPLETED.

Last reviewed 2012-02-01 · How we verify

A Phase 3b Multicenter, Single-Blind Trial to Evaluate the Efficacy of Dexlansoprazole MR 30 mg in Maintaining Control of Gastroesophageal Reflux Disease Symptoms in Subjects on Prior Twice Daily Proton Pump Inhibitor Therapy

NCT00847808 Phase 3 COMPLETED Results posted

The purpose of this study is to determine if patients with well-controlled heartburn symptoms on twice-daily proton pump inhibitor therapy remain well-controlled after stepping down to once-daily (QD) dexlansoprazole modified release (MR) 30 mg.

Details

Lead sponsor	Takeda
Phase	Phase 3
Status	COMPLETED
Enrolment	178
Start date	2009-02
Completion	2010-04

Conditions

Gastroesophageal Reflux

Interventions

Dexlansoprazole MR QD

Primary outcomes

Proportion of Participants Who Remain Well Controlled After Switching From Their Current Twice-daily Proton Pump Inhibitor Therapy to Dexlansoprazole MR. — Week 3 through Week 6
Well-controlled participants were defined to be participants who completed the study having at least 23 days of evaluable diary entries between Days 15 and 42, inclusive, and had ≤4 occurrences of heartburn during this period.

Countries

United States